<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Macrogenics Inc — News on 6ix</title>
<link>https://6ix.com/company/macrogenics-inc</link>
<description>Latest news and press releases for Macrogenics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 08 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/macrogenics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683598b978dffbe2df1058bd.webp</url>
<title>Macrogenics Inc</title>
<link>https://6ix.com/company/macrogenics-inc</link>
</image>
<item>
<title>FDA Removes Partial Clinical Hold on MacroGenics’ LINNET Study</title>
<link>https://6ix.com/company/macrogenics-inc/news/fda-removes-partial-clinical-hold-on-macrogenics-linnet-study</link>
<guid isPermaLink="true">https://6ix.com/company/macrogenics-inc/news/fda-removes-partial-clinical-hold-on-macrogenics-linnet-study</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>• Plan to resume enrollment in clinical study of lorigerlimab in gynecologic cancers • On track to provide mid-2026 program update ROCKVILLE, MD, April 08,</description>
</item>
<item>
<title>MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures</title>
<link>https://6ix.com/company/macrogenics-inc/news/macrogenics-reports-2025-financial-results-and-highlights-upcoming-planned-data-disclosures-1</link>
<guid isPermaLink="true">https://6ix.com/company/macrogenics-inc/news/macrogenics-reports-2025-financial-results-and-highlights-upcoming-planned-data-disclosures-1</guid>
<pubDate>Mon, 09 Mar 2026 20:01:00 GMT</pubDate>
<description>Initial MGC026 (B7-H3 ADC) Phase 1 results in mid-2026Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026Lorigerlimab Phase 2 LINNET study update in mid-2026IND submission for MGC030, a first-in-class TOP1i-based ADC, on track for 3Q 2026Cash, cash equivalents and marketable securities of $189.9 million as of December 31, 2025; cash runway guidance remains into late 2027 ROCKVILLE, Md., March 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmac</description>
</item>
<item>
<title>MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial</title>
<link>https://6ix.com/company/macrogenics-inc/news/macrogenics-announces-pausing-of-enrollment-of-new-study-participants-in-linnet-trial</link>
<guid isPermaLink="true">https://6ix.com/company/macrogenics-inc/news/macrogenics-announces-pausing-of-enrollment-of-new-study-participants-in-linnet-trial</guid>
<pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
<description>FDA has placed partial clinical hold on LINNET study of lorigerlimab in gynecologic cancer ROCKVILLE, MD, Feb. 23, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc.</description>
</item>
<item>
<title>MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference</title>
<link>https://6ix.com/company/macrogenics-inc/news/macrogenics-participate-8th-annual-evercore-210500071</link>
<guid isPermaLink="true">https://6ix.com/company/macrogenics-inc/news/macrogenics-participate-8th-annual-evercore-210500071</guid>
<pubDate>Tue, 25 Nov 2025 21:05:00 GMT</pubDate>
<description>ROCKVILLE, MD, Nov. 25, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, at 7:55 am ET in Miami, FL. A webcast of the presentation may be accessed under "Events & Presentations" in the Investor</description>
</item>
<item>
<title>MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress</title>
<link>https://6ix.com/company/macrogenics-inc/news/macrogenics-reports-third-quarter-2025-210100888</link>
<guid isPermaLink="true">https://6ix.com/company/macrogenics-inc/news/macrogenics-reports-third-quarter-2025-210100888</guid>
<pubDate>Wed, 12 Nov 2025 21:01:00 GMT</pubDate>
<description>Achieved additional $75 million in partnering proceeds from Sanofi and GileadGranted license to additional preclinical program to Gilead that leverages MacroGenics’ novel T-cell engager platformRealigned pipeline priorities by ending development of lorigerlimab in prostate cancer while continuing development in ovarian cancerCash runway guidance extended into late 2027 ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on devel</description>
</item>
<item>
<title>MacroGenics to Participate in the Stifel 2025 Healthcare Conference</title>
<link>https://6ix.com/company/macrogenics-inc/news/macrogenics-participate-stifel-2025-healthcare-213000333</link>
<guid isPermaLink="true">https://6ix.com/company/macrogenics-inc/news/macrogenics-participate-stifel-2025-healthcare-213000333</guid>
<pubDate>Thu, 06 Nov 2025 21:30:00 GMT</pubDate>
<description>ROCKVILLE, MD, Nov. 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside chat at the Stifel 2025 Healthcare Conference on Thursday, November 13, 2025, at 4:00 pm ET in New York, NY. A webcast of the presentation may be accessed under "Events & Presentations" in the Investo</description>
</item>
<item>
<title>MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/macrogenics-inc/news/macrogenics-present-h-c-wainwright-203000327</link>
<guid isPermaLink="true">https://6ix.com/company/macrogenics-inc/news/macrogenics-present-h-c-wainwright-203000327</guid>
<pubDate>Tue, 02 Sep 2025 20:30:00 GMT</pubDate>
<description>ROCKVILLE, MD, Sept. 02, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that MacroGenics’ President & Chief Executive Officer, Eric Risser, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025, at 11:30am ET in New York, NY. A webcast of the above presentation may be accessed under "Events & Presenta</description>
</item>
<item>
<title>MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities</title>
<link>https://6ix.com/company/macrogenics-inc/news/macrogenics-reports-second-quarter-2025-200100139</link>
<guid isPermaLink="true">https://6ix.com/company/macrogenics-inc/news/macrogenics-reports-second-quarter-2025-200100139</guid>
<pubDate>Thu, 14 Aug 2025 20:01:00 GMT</pubDate>
<description>Newly-appointed President and CEO, Eric Risser, outlines strategic priorities for 2025 and 2026 Received $70 million upfront cash payment from Sagard Healthcare Partners under a royalty purchase agreement for ZYNYZ® Cash, cash equivalents and marketable securities of $176.5 million as of June 30, 2025; cash runway through first half of 2027 ROCKVILLE, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovati</description>
</item>
<item>
<title>MacroGenics Appoints Eric Risser as President and Chief Executive Officer</title>
<link>https://6ix.com/company/macrogenics-inc/news/macrogenics-appoints-eric-risser-president-200100072</link>
<guid isPermaLink="true">https://6ix.com/company/macrogenics-inc/news/macrogenics-appoints-eric-risser-president-200100072</guid>
<pubDate>Wed, 13 Aug 2025 20:01:00 GMT</pubDate>
<description>ROCKVILLE, MD, Aug. 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company developing innovative antibody-based therapeutics for the treatment of cancer, today announced that effective as of August 13, 2025, Eric Risser has been appointed President, Chief Executive Officer and to the Board of Directors. Mr. Risser has served as Chief Operating Officer at MacroGenics since 2022, overseeing several key company functions and has led the Company’s c</description>
</item>
<item>
<title>MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement</title>
<link>https://6ix.com/company/macrogenics-inc/news/macrogenics-sagard-healthcare-partners-enter-110000566</link>
<guid isPermaLink="true">https://6ix.com/company/macrogenics-inc/news/macrogenics-sagard-healthcare-partners-enter-110000566</guid>
<pubDate>Tue, 10 Jun 2025 11:00:00 GMT</pubDate>
<description>MacroGenics received $70 million upfront cash payment from Sagard Healthcare Partners (Sagard)MacroGenics’ cash runway extended through first half of 2027 ROCKVILLE, MD, June 10, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that it has entered into a royalty purchase agreement with Sagard</description>
</item>
<item>
<title>MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025</title>
<link>https://6ix.com/company/macrogenics-inc/news/macrogenics-present-goldman-sachs-46th-203000749</link>
<guid isPermaLink="true">https://6ix.com/company/macrogenics-inc/news/macrogenics-present-goldman-sachs-46th-203000749</guid>
<pubDate>Tue, 03 Jun 2025 20:30:00 GMT</pubDate>
<description>ROCKVILLE, MD, June 03, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company’s management team will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10, 2025, at 8:00am ET in Miami, FL. A webcast of the above presentation may be accessed und</description>
</item>
<item>
<title>MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/macrogenics-inc/news/macrogenics-provides-corporate-progress-first-200100602</link>
<guid isPermaLink="true">https://6ix.com/company/macrogenics-inc/news/macrogenics-provides-corporate-progress-first-200100602</guid>
<pubDate>Tue, 13 May 2025 20:01:00 GMT</pubDate>
<description>First patient dosed in LINNET Phase 2 study of lorigerlimab in ovarian and other gynecologic cancers Clinical update on LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPC, expected in second half of 2025 Advancement in portfolio of innovative ADC product candidates, including MGC026, MGC028 and MGC030 Cash, cash equivalents and marketable securities of $154.1 million as of March 31, 2025 ROCKVILLE, Md., May 13, 2025 (GLOBE NEWSWI</description>
</item>
<item>
<title>MacroGenics Announces Date of First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/macrogenics-inc/news/macrogenics-announces-date-first-quarter-203000947</link>
<guid isPermaLink="true">https://6ix.com/company/macrogenics-inc/news/macrogenics-announces-date-first-quarter-203000947</guid>
<pubDate>Tue, 06 May 2025 20:30:00 GMT</pubDate>
<description>ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2025 after the market closes on Tuesday, May 13, 2025. The Company will not be hosting a conference call to discuss its financial results or corporate progress f</description>
</item>
<item>
<title>MacroGenics to Participate in Upcoming Investor Conference</title>
<link>https://6ix.com/company/macrogenics-inc/news/macrogenics-participate-upcoming-investor-conference-203000800</link>
<guid isPermaLink="true">https://6ix.com/company/macrogenics-inc/news/macrogenics-participate-upcoming-investor-conference-203000800</guid>
<pubDate>Thu, 01 May 2025 20:30:00 GMT</pubDate>
<description>ROCKVILLE, MD, May 01, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company's management team will participate in the following investor conference this month: The Citizens Life Sciences Conference (New York). Members of MacroGenics’ management team will participate in a fireside cha</description>
</item>
<item>
<title>MacroGenics Provides Update on Corporate Progress and 2024 Financial Results</title>
<link>https://6ix.com/company/macrogenics-inc/news/macrogenics-provides-corporate-progress-2024-200200043</link>
<guid isPermaLink="true">https://6ix.com/company/macrogenics-inc/news/macrogenics-provides-corporate-progress-2024-200200043</guid>
<pubDate>Thu, 20 Mar 2025 20:02:00 GMT</pubDate>
<description>Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating new LINNET Phase 2 study of lorigerlimab in ovarian cancerAdvancing multiple novel topoisomerase 1 inhibitor-based ADCs, including MGC026, MGC028 and MGC030Discontinuing further internal clinical development of vobra duo; exploring potential partneringCash, cash equivalents and marketable securities of $201.7 million as of December 31, 2024; cash runway e</description>
</item>
<item>
<title>MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call</title>
<link>https://6ix.com/company/macrogenics-inc/news/macrogenics-announces-date-fourth-quarter-123000959</link>
<guid isPermaLink="true">https://6ix.com/company/macrogenics-inc/news/macrogenics-announces-date-fourth-quarter-123000959</guid>
<pubDate>Thu, 06 Mar 2025 12:30:00 GMT</pubDate>
<description>ROCKVILLE, MD, March 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter and full year of 2024 after the market closes on Thursday, March 20, 2025. MacroGenics will host a conference call to discuss the financial results and recent co</description>
</item>
<item>
<title>MacroGenics to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/macrogenics-inc/news/macrogenics-participate-upcoming-investor-conferences-123000700</link>
<guid isPermaLink="true">https://6ix.com/company/macrogenics-inc/news/macrogenics-participate-upcoming-investor-conferences-123000700</guid>
<pubDate>Thu, 27 Feb 2025 12:30:00 GMT</pubDate>
<description>ROCKVILLE, MD, Feb. 27, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in March: TD Cowen 45th Annual Healthcare Conference (Boston). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will partici</description>
</item>
<item>
<title>MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results</title>
<link>https://6ix.com/company/macrogenics-inc/news/macrogenics-provides-update-on-corporate-progress-third-quarter-2024-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/macrogenics-inc/news/macrogenics-provides-update-on-corporate-progress-third-quarter-2024-financial-results</guid>
<pubDate>Tue, 05 Nov 2024 05:00:00 GMT</pubDate>
<description>Strengthened financial position resulting from recently announced MARGENZA® transaction and previously announced receipt of milestone payment from Incyte</description>
</item>
<item>
<title>MacroGenics Announces Leadership Transition</title>
<link>https://6ix.com/company/macrogenics-inc/news/macrogenics-announces-leadership-transition</link>
<guid isPermaLink="true">https://6ix.com/company/macrogenics-inc/news/macrogenics-announces-leadership-transition</guid>
<pubDate>Wed, 30 Oct 2024 04:00:00 GMT</pubDate>
<description>Scott Koenig, M.D., Ph.D., to step down as President and CEOBoard to initiate search process to identify new CEO ROCKVILLE, MD, Oct. 30, 2024 (GLOBE NEWSWIRE)</description>
</item>
<item>
<title>MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call</title>
<link>https://6ix.com/company/macrogenics-inc/news/macrogenics-announces-date-of-third-quarter-2024-financial-results-conference-call</link>
<guid isPermaLink="true">https://6ix.com/company/macrogenics-inc/news/macrogenics-announces-date-of-third-quarter-2024-financial-results-conference-call</guid>
<pubDate>Tue, 29 Oct 2024 04:00:00 GMT</pubDate>
<description>ROCKVILLE, MD, Oct. 29, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and</description>
</item>
</channel>
</rss>